The pharmacologic management of insomnia in patients with HIV

Journal of Clinical Sleep Medicine

Volumn 5, Issue 3, 2009, Pages 251-262

  Omonuwa, Toma S ^a   Goforth, Harold W ^b   Preud'homme, Xavier ^a   Krystal, Andrew D ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

HIV; Insomnia; Pharmacotherapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CYTOCHROME P450;

CLINICAL PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MEDLINE; OPPORTUNISTIC INFECTION; QUALITY OF LIFE; REVIEW;

EID: 67650472819     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.27496     Document Type: Review

References (105)

1. Edinger JD, Bonnet MH, Bootzin RR, et al. Derivation of research diagnostic criteria for insomnia: report of an American Academy of Sleep Medicine Work Group. Sleep 2004;27:1567-1596 (Pubitemid 40041627)
2. Reid S, Dwyer J. Insomnia in HIV infection: a systematic review of prevalence, correlates and management. Psychosom Med 2005;67:260-269 (Pubitemid 40410962)
3. Rubinstein ML, Selwyn PA. High Prevalence of insomnia in an outpatient population with HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:260-265 (Pubitemid 28489748)
4. Norman SE, Chediak AD, Freeman C, et al. Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection. Sleep 1992;15:150-155
5. Norman SE, Chediak AD, Kiel M, Cohn MA. Sleep disturbances in HIV-infected homosexual men. AIDS 1990;4:775-781 (Pubitemid 20267173)
6. Kubicki S, Henkes H, Terstegge K, Ruf B. AIDS related sleep disturbances - a preliminary report. In: Kubicki, Henkes, Bienzle, Pohle, eds. HIV and the nervous system. Stuttgart: Gustav Fischer; 1988:97-105.
7. Wiegand M, Möller AA, Schreiber W, et al. Nocturnal sleep EEG in patients with HIV infection. Eur Arch Psychiatry Clin Neurosci 1991;240:153-158
8. Omonuwa, T, Edinger J, Goforth H, et al. Study comparing PSG data in Insomnia patients with HIV versus matched controls with insomnia. Sleep 2008;31. Abstract supplement
9. Moeller AA, Oechsner M, Backmund HC, Popescu M, Emminger C, Holsboer F. Self-reported sleep quality in HIV infection: correlation to the stage of infection and zidovudine therapy. J Acquir Immune Defic Syndr 1991;4:1000-1003
10. Darko DF, McCutchan JA, Kripke DF, Gillin JC, Golshan S. Fatigue, sleep disturbance, disability, and indices of progression of HIV infection. Am J Psychiatry 1992;149:514-520
11. Nunez M, de Requena DG, Gallego L, Jiménez-Nácher I, González-Lahoz J, Soriano V. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immun Defic Syndr Human Retrovirol 2001;28:399-400. (Pubitemid 33101295)
12. Fumaz CR, Tuldra A, Ferrer MJ, et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immun Defic Syndr Human Retrovirol 2002; 29:244-253 (Pubitemid 34208532)
13. Gallego L, Barreiro P, del Rio R, et al. Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis 2004;38:430-432 (Pubitemid 38200124)
14. Ammassari A, Murri R, Pezzotti P, et al. AdiCONA Study Group. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001;28:445-449 (Pubitemid 34033195)
15. Phillips KD, Skelton WD. Effects of individualized acupuncture on sleep quality in HIV disease. J Assoc Nurses AIDS Care 2001;12:27-39.
16. Dreher HM. The effect of caffeine reduction on sleep quality and well being in persons with HIV. J Psychosom Res 2003;54:191-198 (Pubitemid 36388856)
17. Bock KW, Lilienblum W, Fischer G, Schirmer G, Bock-Henning BS. The role of conjugation reactions in detoxication. Arch Toxicol 1987;60:22-29
18. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Developed by the DHHS Panel on Antiretroviral guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council, December 1, 2007. http://AIDSinfo.nih.gov.
19. Adkins JC, Noble S. Efavirenz. Drugs. 1998;56:1055-1056
20. James JS. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination. AIDS Treat News 1998;299:1-3.
21. Usami O, Ashino Y, Komaki Y, et al. Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 *2/*2 (C64T). Int J STD AIDS 2007;18:575-576 (Pubitemid 351738951)
22. Motwani B, Khayr W. Pharmacoenhancement of protease inhibitors. Am J Ther 2006;13:57-63
23. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-291
24. Atazanavir package insert, Bristol-Myers Squibb, Princeton, NJ. Revised March, 2008
25. Indinavir product package insert, Merck, West Point PA. 1998
26. Nelfinavir package insert, Agouron Pharmaceuticals, La Jolla, CA. Revised August, 2007
27. Saquinavir package insert, Roche Pharmaceuticals, Nutley, NJ. July 2007
28. Hanna L. T-20: first of a new class of anti-HIV drugs. BETA. 1999;12:7-8.
29. Graybill JR, Lundberg D, Donovan W, Levine HB, Rodriguez MD, Drutz DJ. Treatment of coccidioidomycosis with ketoconazole: clinical and laboratory studies of 18 patients. Rev Infect Dis 1980;2:661-673
30. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987;31:1874-1878 (Pubitemid 18009552)
31. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Interaction of triazolam and ketoconazole. Lancet 1995;345:191.
32. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601. (Pubitemid 124006567)
33. Szczech LA, Hoover DR, Feldman JG, et al. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy. Clin Infect Dis 2004;39:1199-1206 (Pubitemid 40169320)
34. Gardner LI, Holmberg SD, Williamson JM, et al; HIV Epidemiology Research Study Group. Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr 2003;32:203-209
35. Gupta SK, Mamlin BW, Johnson CS, Dollins MD, Topf JM, Dube MP. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. Clin Nephrol 2004;61:1-6. (Pubitemid 38100837)
36. Abbott KC, Hypolite, I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States Patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001;14:377-383 (Pubitemid 33080979)
37. Herman ES, Klotman PE. HIV-associated nephropathy: Epidemiology, pathogenesis and treatment. Semin Nephrol 2003;23:200-208 (Pubitemid 36397102)
38. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients coinfected with human immunodeficiency virus: a crosssectional analysis of the U.S. Adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837 (Pubitemid 34194855)
39. Coinfection with HIV and Hepatitis C Virus. Centers for Disease Control (CDC). November, 2005.
40. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-1058 (Pubitemid 29458296)
41. Benhamou Y, DiMartino V, Bochet M, et al; MutlivirC Group. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34:283-287
42. Velissaris D, Solomou E, Kalogeropoulos A, Georgiopoulou V, Thomopoulos C, Karatza C. Sleep disorders and brain MRI as early indicators of subclinical hepatic encephalopathy. Hepatogastroenterology 2006;53:51-54 (Pubitemid 43287393)
43. Juhl RP, Van Thiel DH, Dittert LW, Smith RB. Alprazolam pharmacokinetics in alcoholic liver disease. J Clin Pharmacol 1984;24:113-119 (Pubitemid 14128713)
44. Pentikainen PJ, Valisalm L, Himberg JJ, Crevoisier C. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989;29:272-277 (Pubitemid 19087927)
45. Kroboth PD, Smith RB, Van Thiel DH, Juhl RP. Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. J Clin Pharmacol 1987;27:555-560 (Pubitemid 17133097)
46. Bakti G, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 1987;7:629-638 (Pubitemid 17130703)
47. Hoyumpa AM, Schenker S. Is glucuronidation truly preserved in patients with liver disease? Hepatology 1991;13:786-795
48. Rodighiero V. Effects of Liver disease on pharmacokinetics: An update. Clin Pharmacokinet 1999;37:399-431.
49. Celentano DD, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Infect Dis 2007;45:318-323
50. Jaffe JH, Bloor R, Crome I, Carr M, Alam F, Simmons A, Meyer RE. A postmarketing study of relative abuse liability of hypnotic sedative drugs. Addiction 2004;99:165-173 (Pubitemid 38250751)
51. Krystal AD. A compendium of placebo-controlled trials of the risks/benefits of pharmacologic treatments for insomnia: the empirical basis for clinical practice. Sleep Med Rev In Press.
52. Dordain G, Puech AJ, Simon P. Triazolam compared with nitrazepam and with oxazepam in insomnia: two double-blind, crossover studies analyzed sequentially. Br J Clin Pharmacol 1981;11:43S-49S. (Pubitemid 11098012)
53. Kroboth PD, Julh RP. New drug evaluations. Triazolam. Drug Intell Clin Pharm 1983;17:495-500.
54. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defie Syndr 2000;24:129-136 (Pubitemid 30640958)
55. Ankier SI, Goa KL. Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs 1988;35:42-62.
56. Fraschini F, Stankov B. Temazepam: pharmacological profile of a benzodiazepine and new trends in its clinical application. Pharmacol Res 1993;27:97-113. (Pubitemid 23123051)
57. McElnay JC, Jones ME, Alexander B. Temazepam (Restoril, Sandoz Pharmaceuticals). Drug Intell Clin Pharm 1982;16:650-656
58. Mole L, Israelski D, Bubp J, O'Hanley P, Merigan T, Blaschke T. Pharmacokinetics of zidovudine alone and in combination with oxazepam in the HIV infected patient. J Acquir Immune Defic Syndr 1993;6:56-60 (Pubitemid 23039259)
59. Goetestam KG, Oppoeyen F, Berntzen D. Treatment of insomnia with two benzodiazepines: a double-blind crossover study. Eur J Clin Pharmacol 1991;41:137-140
60. Bliwise D, Seidel W, Greenblatt DJ, Dement W. Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia. Am J Psychiatry 1984;141:191-195 (Pubitemid 14180956)
61. Gallais H, Casanova P, Fabregat H. Midazolam and oxazepam in the treatment of insomnia in hospitalized patients. Br J Clin Pharmacol 1983;16:145S-149S
62. Li Pi Shan RS, Ashworth NL. Comparison of lorazepam and zopiclone for insomnia in patients with stroke and brain injury: a randomized, crossover, double-blinded trial. Am J Phys Med Rehabil 2004;83:421-427 (Pubitemid 38658129)
63. Buysse DJ, Reynolds CF 3rd, Houck PR, et al. Does lorazepam impair the antidepressant response to nortriptyline and psychotherapy? J Clin Psychiatry 1997;58:426-432
64. McClure DJ, Walsh J, Chang H, Olah A, Wilson R, Pecknold JC. Comparison of lorazepam and flurazepam as hypnotic agents in chronic insomniacs. J Clin Pharmacol 1988;28:42-63.
65. Elliot HW. Metabolism of lorazepam. Br J Anaesth 1976;48:1017-23.
66. Greenblatt, D, von Moltke LL, Harmatz JS, et al. Alprazolamritonavir interaction: Implications for product labeling. Clin Pharmacol Ther 2000;67:335-341 (Pubitemid 30246808)
67. Sabbatini M, Crispo A, Pisani A, et al. Zaleplon improves sleep quality in maintenance hemodialysis patients. Nephron Clin Pract 2003;94:99-103.
68. Eszopiclone package insert. Sepracor. Marlborough, MA, 2007.
69. Walsh JK. Drugs used to treat insomnia in 2002: regulatory- based rather than evidence based medicine. Sleep 2004;27:1441-1442
70. Potter WZ, Manji HK, Rudorfer MV. Tricyclics and tetracyclics. In: Schatzberg AF, Nemeroff CB eds. Textbook of psychopharmacology, 2nd ed. Washington DC: American Psychiatric Press,1998: 199-218.
71. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 2007;30:1555-1561 (Pubitemid 350036981)
72. Kirchheiner J, Meineke I, Müller G, Roots I, Brockmöller J. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002;12:571-580
73. Virtanen R, Scheinin M, Iisalo E. Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol 1980;47:371-376 (Pubitemid 11197363)
74. Hartter S, Tybring G, Friedberg T, Weigmann H, Hiemke C. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 2002;19:1034-1037 (Pubitemid 34804247)
75. Elavil Prescribing Information. Astra Zeneca Pharmaceuticals, Wilmington, DE. 2008
76. Ziegler VE, Biggs JT, Ardekani AB, Rosen SH. Contribution to the pharmacokinetics of amitriptyline. J Clin Pharmacol 1978;18:462-467
77. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998;38:112-121 (Pubitemid 28117366)
78. De Boer T, Ruigt GSF. The selective α2-adrenoreceptor antagonist Org 3770 (mirtazapine) enhances noradrenergic and serotonin1A- mediated serotonergic neurotransmission. CNS Drugs 1995;4:29-38
79. Timmer JC, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000;38:461-474.
80. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disorders 1998;51:267-285 (Pubitemid 29202175)
81. Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1143-1145 (Pubitemid 43928210)
82. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000;28:1168-1175 (Pubitemid 30747324)
83. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry 2005 66:469-476 (Pubitemid 40593575)
84. Walsh JK, Erman M, Erwin CW, et al. Subjective hypnotic efficacy of trazodone and zolpidem in DSM-III-R primary insomnia. Hum Psychopharmacol 1998;13:191-198 (Pubitemid 28216251)
85. Conn JP, Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1C) receptors. J Pharmacol Exp Ther 1987;242:552-557 (Pubitemid 17143488)
86. Fiorella D, Rabin RA, Winter JC. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of m-chlorophenylpiperazine. Psychopharmacology 1995;119:222-230
87. Kahn RS, Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biol Psychiatry 1991;30:1139-1166
88. Rotzinger S, Fang J, Baker GB. Trazodone Is metabolized to m-chlorophenylpiperazine by cyp3a4 from human sources. Drug Metab Dispos 1998;26:572-575 (Pubitemid 28498363)
89. Tancer ME, Johanson CE. The subjective effects of MDMA and mCPP in moderate MDMA Users. Drug Alcohol Depend 2001;65:97-101. (Pubitemid 33063665)
90. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003;43:414-422 (Pubitemid 36368783)
91. Ishida M, Otani K, Kaneko S, et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995;10:143-146
92. Rotzinger S, Fang J, Coutts RT, Baker GB. Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 1998;44:1185-1191
93. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24. (Pubitemid 46148428)
94. Kelly DV, Beique LC, Bowmer MI. Extrapyramidal symptoms with ritonavir/indinavir plus risperidone. Ann Pharmacother 2002;36:827-830 (Pubitemid 34517413)
95. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2008;13:27-35. (Pubitemid 350275185)
96. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-F58. (Pubitemid 28190689)
97. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96. (Pubitemid 26053226)
98. Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995;10:239-244
99. Markowitz JS, DeVane CL, Malcolm RJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2006;46:164-171 (Pubitemid 43146447)
100. Penzak SR, Hon YY, Lawhorn WD, Shirley KL, Spratlin V, Jann MW. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 2002; 22:366-370 (Pubitemid 34810325)
101. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38:393-414. (Pubitemid 30265260)
102. Wiegand MH, Landry F, Bruckner T, Pohl C, Vesely Z, Jahn T. Quetiapine in primary insomnia: a pilot study. Psychopharmacology 2008;196:337-338
103. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:521-533 (Pubitemid 30419077)
104. Koppel BS, Bharel C. Use of amitriptyline to offset sleep disturbances caused by efavirenz. AIDS Patient Care STDS 2005;19:419-420 (Pubitemid 41105520)
105. Kalucy RS. Drug-induced weight gain. Drugs 1980;19:268-278